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Abstract
Given the key role of lenalidomide in the treatment of relapsed/refractory multiple myeloma, it is important to
evaluate the safety of lenalidomide in real-world populations of patients who may not qualify for clinical trial
participation. This noninterventional, European post-authorization safety study confirms that the real-world
safety profile of lenalidomide is similar to what has been reported in clinical trials.
Introduction: Lenalidomide plus dexamethasone is effective and well tolerated in relapsed/refractory multiple
myeloma (RRMM). In this observational, noninterventional European post-authorization safety study, the safety profile
of lenalidomide plus dexamethasone was investigated and compared with that of other agents in the treatment of
RRMM in a real-world setting. Patients and Methods: Patients had received  1 prior antimyeloma therapy; prior
lenalidomide was excluded. Treatment was per investigator’s routine practice. Adverse events were analyzed by
incidence rates per 100 person-years to account for differences in observation length and treatment duration. Results:
In total, 2150 patients initiated lenalidomide, and 1479 initiated any other antimyeloma therapy, predominately
bortezomib (80.3%), which was primarily administered intravenously (74.3%). The incidence rate of neuropathy was
lower with lenalidomide (10.5) than with bortezomib (78.9) or thalidomide (38.7). Lenalidomide also had a lower
incidence rate of infections (68.7) versus bortezomib (95.9) and thalidomide (76.0). Conversely, the incidence rate of
neutropenia was higher with lenalidomide (38.0) than with bortezomib (18.2) or thalidomide (25.7). The incidence rates
of thrombocytopenia were 24.4, 40.4, and 14.4 with lenalidomide, bortezomib, and thalidomide, respectively.1Department ofHematology, Azienda USLe IRCCS di Reggio Emilia, Reggio Emilia, Italy
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European Lenalidomide Post-Authorization RRMM Safety StudyConclusion: No new safety signals for lenalidomide were identified in this study, which is the largest prospective real-
world European study of lenalidomide in patients with RRMM to date. These results confirm that the safety profile of
lenalidomide plus dexamethasone in RRMM in a real-world setting is comparable to that reported in clinical trials.
Clinical Lymphoma, Myeloma & Leukemia, Vol. 20, No. 10, e629-44 ª 2020 Published by Elsevier Inc.
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Patient outcomes in multiple myeloma (MM) have improved
since the introduction of effective, novel treatments, but the disease
is still not considered curable, and most patients will experience
relapse or progressive disease (PD) even after autologous stem cell
transplant.1-4 Furthermore, the disease course of MM is character-
ized by the development of drug resistance and increased genetic
heterogeneity.5-10 Thus, recurrent myeloma tends to become more
aggressive with each relapse and is associated with worse patient
outcomes.11
The immunomodulatory drug lenalidomide is an established
agent in MM pharmacotherapy.12 Lenalidomide exerts direct
immunomodulatory and tumoricidal effects by modulating the E3
ligase protein cereblon.13-16 This triggers proteasomal degradation
of the transcription factors Ikaros and Aiolos, leading to
downregulation of IRF4 and c-MYC and upregulation of
interleukin 2.14,16,17 The efficacy of lenalidomide plus dexametha-
sone is greater than that of lenalidomide alone.18-20 Indeed,
this regimen is effective and well tolerated in patients with relapsed/
refractory MM (RRMM), as demonstrated by 2 large, randomized,
double-blind, phase III trials (MM-009 and MM-010).18,19,21 In
both trials, time to progression and overall survival were prolonged
with lenalidomide plus dexamethasone versus placebo plus dexa-
methasone. These trials led to the approval of the combination by
the United States Food and Drug Administration and the European
Commission for the treatment of MM in patients who have
received  1 prior therapy.13,22,23
Given the key role of lenalidomide in the treatment of
RRMM,2,12 accurate understanding of its safety profile, particularly
in patient populations that may not qualify for clinical trial
participation or have access to clinical trials, is critical for clinicians.
Indeed, differences in both patient and disease characteristics be-
tween MM clinical trial and real-world populations can impact re-
ported outcomes.24 Because real-world safety findings regarding the
use of lenalidomide in patients with RRMM are limited, there is a
need for such data. Moreover, because lenalidomide is typically
administered until PD, many patients will receive long-term treat-
ment with lenalidomide. This prolonged exposure may confound
interpretation of safety data. Specifically, adverse events (AEs) are
often reported as percentages, which cannot take into account
length of time on treatment. Thus, incidence rates—the frequency
of events observed over a definite time period—provide enhanced
context for the safety of long-term treatments, especially in com-
parison with fixed-duration therapies.
In this observational, noninterventional European Post-
Authorization Safety Study (EU PASS), the safety of lenalidomide
plus dexamethasone in the treatment of RRMM was investigated in- Clinical Lymphoma, Myeloma & Leukemia October 2020a real-world setting comprising 269 sites across 17 countries in the
European Union. This is the largest prospective real-world Euro-
pean study of lenalidomide in RRMM undertaken to date.
Following are detailed safety data regarding AEs of special interest
with lenalidomide treatment (including both overall percentages
and incidence rates) and comparisons with data from a non-
lenalidomide background cohort comprising primarily patients
who received bortezomib but also thalidomide and other agents.
Patients and Methods
Study Design
The study included a lenalidomide cohort and a background
cohort. Patients in both cohorts had received  1 prior anti-
myeloma therapy and were required to have never received lenali-
domide. Enrolled patients who were treated on the study with
lenalidomide for off-label indications were kept in the study. To
achieve a patient population reflective of those treated in real-world
clinical practice, there were few restrictions on eligibility. Exclusion
criteria were refusal to participate in the study, concurrent partici-
pation in an interventional clinical trial, and previous exposure to
lenalidomide. Patients in the lenalidomide cohort commenced
lenalidomide treatment, whereas those in the background cohort
commenced a therapy other than lenalidomide. Patients previously
enrolled in the background cohort who were subsequently pre-
scribed lenalidomide as a new line of treatment could re-enter the
study as new patients in the lenalidomide cohort.
Recruitment began in August 2008 and ended once 1500 pa-
tients in the lenalidomide cohort began the third treatment cycle; up
to 1500 patients could be enrolled in the background cohort. The
sample size was determined based on incidences of AEs of special
interest reported in the MM-009 and MM-010 RRMM clinical
trials.18,19 Data from these trials indicated that 83% of patients
completed  3 months of study intervention. Thus, it was esti-
mated that enrolling approximately 1800 patients would provide for
1500 patients at 3 months. Treatment was per the routine practice
of the investigator, and all participating patients provided written
informed consent. The study protocol was approved by the Com-
mittee for Medicinal Products for Human Use and each center’s
institutional review board or independent ethics committee, as
applicable. The final data cutoff was August 31, 2017.
Study Objectives
The primary objectives of the study were to characterize and
assess the incidence of AEs of special interest in patients with
RRMM treated with lenalidomide in a real-world setting and
compare this with the incidence of these AEs in a non-lenalidomide
background cohort. The AEs of special interest represent those
Table 1 Demographic and Baseline Characteristics
Characteristic
Lenalidomide






(n [ 137) Other (n [ 155) Total (n [ 1479)
Age, y
Median (range) 70.0 (25.0-95.0) 69.0 (30.0-93.0) 71.0 (38.0-95.0) 75.0 (44.0-90.0) 70.0 (30.0-95.0)
65 781 (36.3) 416 (35.0) 44 (32.1) 24 (15.5) 484 (32.7)
66-75 794 (36.9) 461 (38.8) 54 (39.4) 54 (34.8) 569 (38.5)
76 575 (26.7) 310 (26.1) 39 (28.5) 77 (49.7) 426 (28.8)
Male 1150 (53.5) 649 (54.7) 77 (56.2) 82 (52.9) 808 (54.6)
Indication for treatment
MM 2080 (96.7) 1185 (99.8) 137 (100) 154 (99.4) 1476 (99.8)
Othera 70 (3.3) 2 (0.2) 0 1 (0.6) 3 (0.2)
Time since MM diagnosis, yb (n ¼ 2148) (n ¼ 1187) (n ¼ 137) (n ¼ 155) (n ¼ 1479)
Median (range) 2.9 (0.0-36.9) 3.0 (0.0-28.7) 3.1 (0.1-23.3) 3.1 (0.1-16.1) 3.0 (0.0-28.7)
ECOG PS
0-2 1734 (80.7) 926 (78.0) 99 (72.3) 106 (68.4) 1131 (76.5)
3-4 60 (2.8) 44 (3.7) 10 (7.3) 6 (3.9) 60 (4.1)
Unknown/missing 356 (16.6) 217 (18.3) 28 (20.4) 43 (27.7) 288 (19.5)
Patients with prior therapies 2127 (98.9) 1176 (99.1) 133 (97.1) 155 (100) 1464 (99.0)
No. prior therapies
0 23 (1.1)c 11 (0.9) 4 (2.9) 0 15 (1.0)
1 950 (44.2) 840 (70.8) 77 (56.2) 82 (52.9) 999 (67.5)
2 685 (31.9) 219 (18.4) 33 (24.1) 46 (29.7) 298 (20.1)
3 271 (12.6) 67 (5.6) 13 (9.5) 16 (10.3) 96 (6.5)
4 126 (5.9) 29 (2.4) 6 (4.4) 8 (5.2) 43 (2.9)
5 53 (2.5) 15 (1.3) 4 (2.9) 3 (1.9) 22 (1.5)
6 42 (2.0) 6 (0.5) 0 0 6 (0.4)
Previous treatment before study drugd
Alkylating agents (including high-dose
treatment)e
1863 (86.7) 1084 (91.3) 117 (85.4) 133 (85.8) 1334 (90.2)
Bortezomib 1436 (66.8) 282 (23.8) 62 (45.3) 72 (46.5) 416 (28.1)
Thalidomide 870 (40.4) 640 (53.9) 36 (26.3) 44 (28.4) 720 (48.7)
Topoisomerase inhibitors 766 (35.6) 323 (27.2) 31 (22.6) 22 (14.2) 376 (25.4)
Thalidomide and bortezomib 172 (8.0) 40 (3.4) 1 (0.7) 11 (7.1) 52 (3.5)
Chemotherapy assigned at baseline in
combination with study drug
Cyclophosphamide 67 (3.1) 175 (14.7) 39 (28.5) 61 (39.4) 275 (18.6)
Doxorubicin 13 (0.6) 58 (4.9) 3 (2.2) 10 (6.5) 71 (4.8)
Melphalanf 7 (0.3) 130 (11.0) 33 (24.1) 68 (43.9) 231 (15.6)
Vincristine 2 (0.1) 2 (0.2) 0 16 (10.3) 18 (1.2)
Other 120 (5.6) 144 (12.1) 21 (15.3) 57 (36.8) 222 (15.0)
Abbreviations: ECOG PS ¼ Eastern Cooperative Oncology Group performance status; IgG ¼ immunoglobulin G; MM ¼ multiple myeloma.
aFor the lenalidomide cohort, “Other” includes 55 patients with off-label indications as well as 15 patients with myeloma-related (on-label) indications, such as “plasma cell myeloma,” “plasma-
cytoma,” “plasma cell leukemia,” and “blood IgG increased.”
bTime since MM diagnosis is calculated as (date of informed consent e date of diagnosis) þ 1; when day is missing, it is estimated as 1; when the month is missing, it is estimated as June.
cThree patients in the lenalidomide cohort with MM had no previous therapies; most of the patients who received lenalidomide with no previous therapies received the study drug for indications other
than MM.
dPrevious treatment exposure at any time before starting study drug.
eMore commonly prescribed alkylating agents included such drugs as melphalan, cyclophosphamide, lomustine, and carmustine.
fMelphalan includes drugs named Melphalan or Alkeran.
Barbara Gamberi et alreported with lenalidomide treatment (and listed in the summary of
product characteristics), including neutropenia, thrombocytopenia,
infections, bleeding events, venous thromboembolism (VTE),cardiac failure, cardiac arrhythmias, QT prolongation, neuropathy,
rash, hypersensitivity, hypothyroidism, and renal failure. Secondary
objectives included monitoring neuropathy in patients with baselineClinical Lymphoma, Myeloma & Leukemia October 2020 - e631
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requirements in women of childbearing potential taking lenalido-
mide, and identification of new safety signals with lenalidomide
treatment.
Assessments
Assessments were conducted per routine clinical practice. AEs
were coded per Medical Dictionary for Regulatory Activities version
18.0. AE severity was graded per National Cancer Institute Com-
mon Terminology Criteria for Adverse Events version 3.0 whenever
possible. Treatment-emergent AEs (TEAEs) were defined as AEs
occurring on or after the first treatment and within 30 days after the
last dose.
Patients were followed for up to 36 months for second primary
malignancy (SPM) assessments per a protocol amendment modi-
fying the design of the study 3 years after trial start. Follow-up
occurred 30 days after ending active treatment and was subse-
quently scheduled for every 6 months. SPMs were identified using
the Medical Dictionary for Regulatory Activities terms under the
“Neoplasms benign, malignant, and unspecified” System Organ
Class. SPMs were assessed as medically important events and re-
ported as serious AEs.
Analyses
Analyses were performed using the safety population (patients
who received  1 dose of treatment). The sample size of 1500 in
the lenalidomide cohort would permit evaluation of AEs with an
incidence of 1/500 to be detected with a 95% CI.
Results
Patients and Treatment
At the data cutoff of August 31, 2017, the safety population
included 3629 patients from 269 sites in 17 European countries. Of
these patients, 2150 (59.2%) were in the lenalidomide cohort, and
1479 (40.8%) were in the background cohort. As permitted by
protocol, 126 (5.9%) patients in the lenalidomide cohort were
previously enrolled in the background cohort. In the background
cohort, 1187 (80.3%) patients received bortezomib, 137 (9.3%)
received thalidomide, and 155 (10.5%) received other agents. Of
the 1187 patients who received bortezomib, 882 (74.3%) received it
intravenously.
Baseline characteristics for the treatment cohorts are shown in
Table 1. The median age was 70.0 years, and most patients had an
Eastern Cooperative Oncology Group performance status of 0 to 2.
The median number of treatments received prior to enrollment was
1, but a smaller proportion of patients in the lenalidomide cohort
(44.2%) than in the bortezomib (70.8%) or thalidomide (56.2%)
subcohort had only 1 prior treatment. Alkylating agents were the
most common previously received antimyeloma medications
(including high-dose treatments) before study enrollment.
The median for the highest dose of lenalidomide achieved was 25
mg, and the median final dose was 15 mg. The average daily dose
was 18.6 mg. The median duration of treatment was 6.6 months
(range, 0.1-97.9 months) for lenalidomide, 4.1 months for borte-
zomib (range, 0-79.4 months), and 4.6 months for thalidomide
(range, 0.2-36.9 months). Figure 1 displays patients under obser-
vation by time for both the lenalidomide and background cohorts.- Clinical Lymphoma, Myeloma & Leukemia October 2020The lenalidomide cohort had an observation period of 2525 person-
years versus 652, 92, and 91 person-years for patients treated with
bortezomib, thalidomide, and other therapies, respectively. At the
time of data cutoff, all patients had discontinued treatment (see
Supplemental Table 1 in the online version). The most common
reason for discontinuation was PD in the lenalidomide cohort
(32.3%) and the thalidomide subcohort (25.5%); in the bortezomib
subcohort, the most common reason was completion of planned
treatment course (35.7%). Treatment discontinuation owing to AEs
appeared similar among patients in the lenalidomide cohort
(22.7%) and the bortezomib (20.1%) and thalidomide (21.2%)
subcohorts. The median time to discontinuation owing to an AE
was 4.4 months in the lenalidomide cohort, 3.5 months in the
bortezomib subcohort, and 2.8 months in the thalidomide sub-
cohort. The mean time to discontinuation owing to an AE was 9.2,
4.2, and 4.1 months, respectively. The disparities in observation
length, duration of treatment, and primary causes of treatment
discontinuation between the lenalidomide cohort and bortezomib
subcohort are likely attributable to the intended courses of treat-
ment for each drug. Per labeled posology, lenalidomide should be
given until PD or intolerance in patients with RRMM.13,22
Conversely, bortezomib, which was the most commonly received
drug in the background cohort, is given as a fixed-duration
treatment.25,26
Adverse Events of Special Interest
To account for differences in observation length and treatment
duration, AEs of special interest were analyzed using incidence rates
per 100 person-years (Table 2). The AEs with the highest incidence
rates overall were infections, neutropenia, thrombocytopenia, and
neuropathy. The incidence rate of neuropathy was much lower in
the lenalidomide cohort (10.5) than in the bortezomib (78.9) or
thalidomide (38.7) subcohort. Likewise, lenalidomide had a lower
incidence rate of infections (68.7) than bortezomib (95.9) or
thalidomide (76.0). Conversely, the incidence rate of neutropenia
was higher with lenalidomide (38.0) than with bortezomib (18.2) or
thalidomide (25.7). The incidence rate of thrombocytopenia was
24.4 in the lenalidomide cohort, which was lower than that in the
bortezomib subcohort (40.4) but higher than that in the thalido-
mide subcohort (14.4). For the remaining AEs of special interest,
incidence rates were generally low irrespective of cohort.
The frequencies of grade 3/4 cardiac failure, cardiac arrhythmias,
bleeding events, renal failure, and rash were low regardless of
intervention (ranging from 0.4% to 4.1% in the lenalidomide
cohort, 0% to 2.6% in the bortezomib subcohort, and 0% to 2.9%
in the thalidomide subcohort) (Table 3). In addition, across all
patients, grade 3/4 VTE was reported infrequently (2.9% in the
lenalidomide cohort, 0.5% in the bortezomib subcohort, and 0% in
the thalidomide subcohort). An apparently similar proportion of
patients across treatment cohorts had  1 previous thromboembolic
event in their medical histories (11.6% in the lenalidomide cohort
and 10.2% in the bortezomib and thalidomide subcohorts).
Thromboembolic prophylaxis was given to patients based on
physician discretion, history of thromboembolism, and recom-
mended use of thromboembolic prophylaxis with lenalidomide.
Medication for thromboembolic prophylaxis (eg, warfarin, aspirin,
low-molecular-weight heparin, and others) was taken at baseline by
Figure 1 Percentage of Patients in the Lenalidomide Cohort Versus the Background Cohort Under Observation by Time. The
Lenalidomide Cohort Experienced a Longer Observation Period Compared With the Background Cohort
aThe period of observation is from day of consent to last contact or last known date alive
Barbara Gamberi et al71.0% of patients in the lenalidomide cohort compared with 31.5%
of patients in the bortezomib subcohort and 64.2% in the thalid-
omide subcohort. Among all patients, hypothyroidism, hypersen-
sitivity, and QT prolongation were rarely reported.
Neuropathy Status
In the lenalidomide cohort, 806 (37.5%) patients had pre-
existing neuropathy (motor and/or sensory) at baseline: 35 (4.3%)
had grade 3 or 4 motor neuropathy and 46 (5.7%) had grade 3 or 4
sensory neuropathy at baseline (see Supplemental Table 2 in the
online version). Neuropathy in patients receiving lenalidomide was
mostly mild to moderate throughout the study, and sensory neu-
ropathy was more common than motor neuropathy. Among pa-
tients with neuropathy, the frequency of grade 3 or 4 motor or
sensory neuropathy was  5% during the first 12 months of
treatment. Moreover, grade 4 events were recorded infrequentlyTable 2 Incidence Rates of AEs of Special Interest
MedDRA SMQ or HLT, IR
per 100 PY (95% CI) Lenalidomide (n [ 2150) Bortezomib (n
Infections 68.7 (64.5-73.2) 95.9 (86.8-
Neutropenia 38.0 (35.2-41.1) 18.2 (14.8-
Thrombocytopenia 24.4 (22.2-26.7) 40.4 (35.0-
Neuropathy 10.5 (9.2-12.0) 78.9 (70.9-
Venous thromboembolism 6.2 (5.2-7.3) 3.0 (1.8-5
Cardiac failure 2.9 (2.3-3.7) 2.4 (1.4-4
Bleeding events 6.8 (5.8-8.0) 10.2 (7.7-1
Rash 5.8 (4.8-6.9) 4.7 (3.1-7
Cardiac arrhythmias 2.9 (2.3-3.7) 4.4 (2.9-6
Abbreviations: AE ¼ adverse event; CI ¼ confidence interval; HLT ¼ high-level term; IR ¼ inciden
Standardized MedDRA Query.
aNo patients reported AEs for these categories, so IRs and CIs were not calculated.throughout the study. Indeed, after baseline, grade 4 motor neu-
ropathy was only reported in 1 patient each at months 2, 4, and 6.
Similarly, grade 4 sensory neuropathy was only reported in 1 patient
each at months 1, 7, 14, and 24. As previously noted, the incidence
rate of neuropathy was markedly lower in the lenalidomide cohort
than in the bortezomib and thalidomide subcohorts. The findings
suggest that pre-existing neuropathy did not worsen in patients
treated with lenalidomide.
Adverse Events
In the lenalidomide cohort, 1999 (93.0%) patients
experienced  1 any-grade TEAE and 1245 (57.9%)
experienced  1 grade 3/4 TEAE (see Supplemental Table 3 in
the online version). In the bortezomib and thalidomide sub-
cohorts, respectively, 973 (82.0%) and 122 (89.1%) patients
experienced  1 any-grade TEAE, and 486 (40.9%) and 60[ 1187) Thalidomide (n [ 137) Other (n [ 155)
106.0) 76.0 (56.2-102.8) 83.5 (62.6-111.5)
22.5) 25.7 (16.0-41.4) 39.6 (27.0-58.2)
46.8) 14.4 (7.7-26.7) 32.8 (21.6-49.8)
87.8) 38.7 (26.0-57.8) 2.7 (0.7-10.6)
.0) ea 4.0 (1.3-12.5)
.2) 1.4 (0.2-9.7) 4.0 (1.3-12.3)
3.4) 5.6 (2.1-14.8) 4.0 (1.3-12.3)
.0) 8.4 (3.8-18.7) 2.7 (0.7-10.9)
.7) ea 4.0 (1.3-12.3)
ce rate; MedDRA ¼ Medical Dictionary for Regulatory Activities; PY ¼ person-years; SMQ ¼
Clinical Lymphoma, Myeloma & Leukemia October 2020 - e633
Table 3 Frequencies of AEs of Special Interesta
MedDRA SMQ or
HLT, n (%)
Lenalidomide Cohort Background Cohort
Lenalidomide (n [ 2150) Bortezomib (n [ 1187) Thalidomide (n [ 137) Other (n [ 155) Total (n [ 1479)
All TEAEs Grade 3/4 TEAEs All TEAEs Grade 3/4 TEAEs All TEAEs Grade 3/4 TEAEs All TEAEs Grade 3/4 TEAEs All TEAEs Grade 3/4 TEAEs
Infections 965 (44.9) 308 (14.3) 386 (32.5) 119 (10.0) 42 (30.7) 19 (3.9) 46 (29.7) 12 (7.7) 474 (32.0) 150 (10.1)
Neutropenia 629 (29.3) 433 (20.1) 87 (7.3) 53 (4.5) 17 (12.4) 10 (7.3) 26 (16.8) 18 (11.6) 130 (8.8) 81 (5.5)
Thrombo-cytopenia 464 (21.6) 216 (10.0) 180 (15.2) 100 (8.4) 10 (7.3) 5 (3.6) 22 (14.2) 6 (3.9) 212 (14.3) 111 (7.5)
Neuropathy 210 (9.8) 30 (1.4) 337 (28.4) 65 (5.5) 24 (17.5) 3 (2.2) 2 (1.3) 0 363 (24.5) 68 (4.6)
Renal failure 176 (8.2) 88 (4.1) 46 (3.9) 31 (2.6) 5 (3.6) 4 (2.9) 5 (3.2) 5 (3.2) 56 (3.8) 40 (2.7)
Bleeding events 144 (6.7) 25 (1.2) 50 (4.2) 11 (0.9) 5 (3.6) 2 (1.5) 3 (1.9) 2 (1.3) 58 (3.9) 15 (1.0)
VTE 132 (6.1) 63 (2.9) 15 (1.3) 6 (0.5) 0 0 3 (1.9) 0 18 (1.2) 6 (0.4)
Rash 122 (5.7) 8 (0.4) 23 (1.9) 0 6 (4.4) 0 2 (1.3) 0 31 (2.1) 0
Cardiac failure 65 (3.0) 28 (1.3) 12 (1.0) 6 (0.5) 1 (0.7) 1 (0.7) 3 (1.9) 3 (1.9) 16 (1.1) 10 (0.7)
Cardiac arrhythmias 64 (3.0) 23 (1.1) 22 (1.9) 10 (0.8) 0 0 3 (1.9) 2 (1.3) 25 (1.7) 12 (0.8)
Hypothyroidism 6 (0.3) 1 (< 0.1) 1 (0.1) 0 0 0 0 0 1 (0.1) 0
Hypersensitivity 5 (0.2) 0 4 (0.3) 0 0 0 0 0 4 (0.3) 0
QT prolongation 0 0 0 0 0 0 0 0 0 0
Abbreviations: AE ¼ adverse event; HLT ¼ high-level term; MedDRA ¼ Medical Dictionary for Regulatory Activities; SMQ ¼ Standardized MedDRA Query; TEAE ¼ treatment-emergent adverse event; VTE ¼ venous thromboembolism.




















Barbara Gamberi et al(43.8%) patients experienced  1 grade 3/4 TEAE. The most
frequently reported TEAEs of any grade in the lenalidomide
cohort were hematologic (neutropenia, anemia, thrombocyto-
penia), followed by the nonhematologic TEAEs of diarrhea, py-
rexia, fatigue, asthenia, constipation, and peripheral neuropathy
(see Supplemental Table 4 in the online version). Peripheral
neuropathy was reported in 4.6% of patients taking lenalidomide
versus 16.8% of those taking bortezomib and 8.0% of those
taking thalidomide. Likewise, hematologic TEAEs (neutropenia,
thrombocytopenia, anemia, and leukopenia) were the most
commonly occurring grade 3/4 TEAEs (Table 4), and pneu-
monia, asthenia, peripheral neuropathy, and renal failure were the
most common nonhematologic grade 3/4 TEAEs.
Dose Modifications
The proportion of patients with  1 related TEAE that led to
treatment discontinuationwas similar between the lenalidomide cohort
(19.0%) and the bortezomib subcohort (17.1%). In the thalidomide
subcohort, 21.2% of patients had  1 related TEAE that led to
treatment discontinuation. The most common related TEAEs that led
to discontinuation were thrombocytopenia (2.5%), neutropenia
(2.3%), and infections (2.0%) in the lenalidomide cohort, peripheral
neuropathy (5.3%) and peripheral sensory neuropathy (2.1%) in the
bortezomib subcohort, and dizziness (2.9%), infections (2.9%), pol-
yneuropathy (2.2%), and constipation (2.2%) in the thalidomide
subcohort. The proportion of patients with a TEAE leading to dose
interruptionwas higher in the lenalidomide cohort (46.2%) than in the
bortezomib (31.2%) and thalidomide (29.2%) subcohorts.
Short-Term Exposure Safety Analysis
A post hoc analysis was performed to compare the safety profiles
for patients in both cohorts for up to 4 months of treatment (see
Supplemental Table 5 in the online version) owing to the difference
in median treatment duration for observation of TEAEs in the
cohorts (6.6 months for the lenalidomide cohort, 4.1 months for
the bortezomib subcohort, and 4.6 months for the thalidomide
subcohort). A period of 4 months was chosen because it corresponds
to the approximate median duration of treatment in the background
cohort and the end of the first 3 cycles of lenalidomide treatment.
For the AEs of special interest, the rate of any-grade TEAEs and
grade 3/4 TEAEs within the first 4 months of study treatment were
generally comparable between the lenalidomide and the background
cohorts as a whole. Grade 3/4 neutropenia was reported more
frequently in the lenalidomide cohort (12.6%) than in the borte-
zomib (4.0%), thalidomide (5.8%), and other (10.3%) subcohorts.
Conversely, grade 3/4 neuropathy was reported less frequently in
the lenalidomide cohort (0.7%) than in the bortezomib (4.3%) and
thalidomide (2.2%) subcohorts; no instances of grade 3/4 neurop-
athy were reported with other treatments. The rate of grade 3/4
VTE was low overall; it was reported in 1.2% of the lenalidomide
cohort and 0.4% of the bortezomib subcohort. No instances of
grade 3/4 VTE were reported in the thalidomide or other sub-
cohorts. In summation, no unexpected differences were noted in the
frequencies of AEs of special interest with short-term treatment
exposure between the lenalidomide and background cohorts.Long-Term Lenalidomide Exposure Safety Analysis
An additional post hoc analysis was performed to assess the safety
of prolonged lenalidomide administration by comparing the fre-
quencies of AEs of special interest during short-term treatment ( 6
months) versus long-term exposure (> 6 months) in the lenalido-
mide cohort (see Supplemental Table 6 in the online version). For
each AE of special interest, the frequencies of patients reporting any-
grade TEAEs and grade 3/4 TEAEs were higher within 6 months of
the start of treatment and lower or stable after > 6 months on
treatment.
Second Primary Malignancies
SPM incidence rates per 100 person-years are reported in
Table 5. Among all patients, the incidence rate of all SPMs was 4.1.
Despite overlap of 95% confidence interval (CI) limits between the
lenalidomide cohort and the subcohorts for some SPM categories,
generalized comparisons may be observed. The incidence rate of all
SPMs was highest in the other (6.5) and bortezomib (6.0) sub-
cohorts. Relative to the bortezomib subcohort, the lenalidomide
cohort had lower incidence rates for all SPMs and invasive SPMs
(including both hematologic and solid tumor SPMs separately) but
a higher incidence rate of noninvasive SPMs. Patients treated with
lenalidomide had a similar incidence rate of invasive SPMs
compared with those treated with thalidomide (2.2 vs. 2.7,
respectively), but higher incidence rates for all other categories; the
thalidomide subcohort had no reported hematologic or noninvasive
SPMs. SPM incidence rates were generally lower with lenalidomide
than with the other therapies, but there were no reported hema-
tologic SPMs in the other subcohort.
Lenalidomide Pregnancy Counseling and Contraception
There were 24 (1.1%) women of childbearing potential in the
lenalidomide cohort. All received counseling at baseline, and 23
reported using some form of contraception, having a tubal sterili-
zation, or having a vasectomized male partner at baseline and during
the study. No pregnancy or potential fetal exposure to lenalidomide
was reported in women of childbearing potential in the lenalido-
mide cohort.
Discussion
To make better informed treatment decisions, physicians need
safety data on lenalidomide use in patients with RRMM who may
not qualify for clinical trials but are still encountered in clinical
practice, especially given that many patients in the real world will
receive long-term treatment. This observational, noninterventional
EU PASS investigated the safety of lenalidomide plus dexametha-
sone in a real-world setting and compared it with that of bortezomib
and other non-lenalidomide agents. When evaluating safety, dura-
tion of treatment is an important consideration; in this study, pa-
tients treated with lenalidomide had a longer duration of treatment
than those treated with non-lenalidomide therapies. Moreover,
although the median duration of treatment in the lenalidomide
cohort was 6.6 months, some patients remained on lenalidomide
treatment for much longer (up to 97.9 months). Another key factor
in safety analyses is the length of observation, which was also longerClinical Lymphoma, Myeloma & Leukemia October 2020 - e635
Table 4 Most Common (‡ 2% of Patients) Grade 3/4 TEAEs in Either Treatment Cohort
System Organ Class
Preferred Term, n (%)a,b
Lenalidomide Cohort Background Cohort
Lenalidomide (n [ 2150) Bortezomib (n [ 1187) Thalidomide (n [ 137) Other (n [ 155)
Grade 3/4 TEAEsc
Related Grade
3/4 TEAEsc Grade 3/4 TEAEsc
Related Grade
3/4 TEAEsc Grade 3/4 TEAEsc
Related Grade
3/4 TEAEsc Grade 3/4 TEAEsc
Related Grade
3/4 TEAEsc
Hematologic 594 (27.6) 509 (23.7) 152 (12.8) 125 (10.5) 16 (11.7) 7 (5.1) 26 (16.8) 21 (13.5)
Neutropenia 371 (17.3) 342 (15.9) 42 (3.5) 38 (3.2) 6 (4.4) 4 (2.9) 14 (9.0) 13 (8.4)
Thrombocytopenia 198 (9.2) 161 (7.5) 87 (7.3) 79 (6.7) 5 (3.6) 1 (0.7) 6 (3.9) 6 (3.9)
Anemia 185 (8.6) 113 (5.3) 38 (3.2) 18 (1.5) 7 (5.1) 1 (0.7) 11 (7.1) 5 (3.2)
Leukopenia 70 (3.3) 59 (2.7) 18 (1.5) 18 (1.5) 0 0 1 (0.6) 1 (0.6)
Infections and infestations 307 (14.3) 110 (5.1) 119 (10.0) 50 (4.2) 19 (13.9) 4 (2.9) 12 (7.7) 6 (3.9)
Pneumonia 104 (4.8) 41 (1.9) 36 (3.0) 18 (1.5) 10 (7.3) 1 (0.7) 3 (1.9) 2 (1.3)
General disorders and
administration-site conditions
187 (8.7) 86 (4.0) 56 (4.7) 25 (2.1) 4 (2.9) 2 (1.5) 14 (9.0) 5 (3.2)
Asthenia 43 (2.0) 26 (1.2) 17 (1.4) 4 (0.3) 0 0 5 (3.2) 2 (1.3)
Nervous system disorders 113 (5.3) 57 (2.7) 89 (7.5) 71 (6.0) 9 (6.6) 5 (3.6) 1 (0.6) 0
Peripheral neuropathy 13 (0.6) 12 (0.6) 40 (3.4) 39 (3.3) 2 (1.5) 1 (0.7) 0 0
Renal and urinary disorders 100 (4.7) 21 (1.0) 40 (3.4) 7 (0.6) 5 (3.6) 0 6 (3.9) 1 (0.6)
Renal failure 44 (2.0) 13 (0.6) 21 (1.8) 2 (0.2) 1 (0.7) 0 2 (1.3) 0
Abbreviations: AE ¼ adverse event; MedDRA ¼ Medical Dictionary for Regulatory Activities; TEAE ¼ treatment-emergent adverse event.
aPatient with multiple occurrences of an AE is counted only once in the AE category.
bSystem organ classes and preferred terms are coded using MedDRA version 18.0. System organ classes and preferred terms are listed in descending order of frequency for all TEAEs for the lenalidomide cohort.




















Table 5 Incidence Rates of SPMs
SPM, IR per 100 PY
(95% CI)a Lenalidomide (n [ 2150) Bortezomib (n [ 1187) Thalidomide (n [ 137) Other (n [ 155)
Total SPMsb 3.6 (2.9-4.5) 6.0 (4.3-8.5) 2.7 (0.7-10.9) 6.5 (2.7-15.6)
Invasive SPMs 2.2 (1.6-2.9) 5.3 (3.7-7.7) 2.7 (0.7-10.9) 3.9 (1.2-12.0)
Solid tumors 1.6 (1.2-2.2) 4.2 (2.8-6.4) 2.7 (0.7-10.9) 3.9 (1.2-12.0)
Hematologic 0.6 (0.3-1.0) 1.2 (0.5-2.6) ec ec
AML 0.1 (0.0d-0.4) 1.0 (0.4-2.4) ec ec
MDS 0.4 (0.2-0.8) 0.2 (0.0e-1.4) ec ec
Other hematologicf 0.0d (0.0g-0.3) ec ec ec
Noninvasive SPMs 1.5 (1.1-2.1) 0.8 (0.3-2.1) ec 3.9 (1.3-12.0)
Abbreviations: AML ¼ acute myeloid leukemia; CI ¼ confidence interval; IR ¼ incidence rate; MDS ¼ myelodysplastic syndrome; PY ¼ person-years; SPM ¼ second primary malignancy.
aPatients who experienced > 1 SPM (eg, 2 types of SPMs) or > 1 episode of an SPM are counted once in each SPM category and once in the total row.
bTotal includes the number of patients with  1 SPM.
cNo patients reported SPMs in these categories, so IRs and CIs were not calculated.
dRounded down from 0.04.
eRounded down from 0.03.
fAdult T-cell lymphoma/leukemia.
gRounded down from 0.01.
Barbara Gamberi et alwith lenalidomide compared with bortezomib, thalidomide, or
other agents. These differences may be attributed to the treatment
schedules of each agent. Per the drug label, lenalidomide is
administered until PD or intolerance, whereas bortezomib (the most
commonly received treatment of the non-lenalidomide therapies in
this study) is typically administered for a fixed treatment period.22,25
To account for the increased length of time that patients received
lenalidomide versus the therapies in the background cohort, inci-
dence rates of the AEs of special interest were assessed in addition to
their raw frequencies.
Compared with bortezomib and thalidomide, lenalidomide had a
lower incidence rate of infections but a higher incidence rate of
neutropenia. The incidence rate of thrombocytopenia with lenali-
domide was lower than that with bortezomib but higher than that
with thalidomide. Most other AEs of special interest—such as
cardiac failure, hypothyroidism, bleeding events, hypersensitivity,
and others—were rarely reported across cohorts. Notably, patients
receiving lenalidomide reported a lower incidence rate of neuropa-
thy than did patients receiving non-lenalidomide therapies, and
lenalidomide-treated patients with baseline neuropathy generally did
not report worsening throughout the study. Based on these results,
the present status of peripheral neuropathy as an important po-
tential risk for patients starting a new line of treatment with lena-
lidomide may require reassessment.
The incidence rates of SPMs in the lenalidomide cohort align with
what has been previously reported with lenalidomide. In a pooled
analysis of the MM-009 and MM-010 RRMM clinical trials, the
overall SPM incidence rate was higher in the lenalidomide group
(3.98; 95%CI, 2.51-6.31) than in the placebo group (1.38; 95%CI,
0.44-4.27).27 The authors attributed this difference to the increased
incidence of nonmelanoma skin carcinomas in the lenalidomide
group (2.40 [95% CI, 1.33-4.33] vs. 0.91 [95% CI, 0.23-3.66]); the
incidence rate of invasive SPMs was not higher in the lenalidomide
group (1.71; 95% CI, 0.86-3.43) than in the placebo group (0.91;
95% CI, 0.23-3.66). The rates of overall SPM incidence (3.6; 95%
CI, 2.9-4.5) and invasive SPM incidence (2.2; 95% CI, 1.6-2.9)reported in the lenalidomide cohort of this EU PASS are similar to
those reported in the lenalidomide group of the pooled analysis. A
review of SPMs by the International Myeloma Working Group
provides additional context, noting no increase in SPM incidence
with lenalidomide plus dexamethasone (without melphalan).28
Data from analyses by time on treatment are also consistent with
the established safety profile of lenalidomide. The short-term
exposure safety analysis, conducted for better comparability of
treatments owing to the differences in median treatment duration
for observation of TEAEs across the treatment cohorts, revealed no
unexpected differences between the lenalidomide and background
cohorts in rates of grade 3/4 AEs of special interest within the first 4
months of study treatment. The long-term lenalidomide exposure
analysis revealed that, across all AEs of special interest, the fre-
quencies of grade 3/4 TEAEs after 6 months of lenalidomide
treatment were lower than or similar to those reported within the
first 6 months. Diarrhea occurred after 6 months in 13.9% (any
grade) and 0.9% (grade 3/4) of patients in the lenalidomide cohort.
Diarrhea was also a related TEAE that led to discontinuation (at any
point during treatment) in 1.1% of patients in the lenalidomide
cohort. It has been hypothesized that late onset of lenalidomide-
related diarrhea may be related to immune-mediated antimyeloma
activity,29 highlighting the need for appropriate AE management
throughout treatment. Overall, these results underscore the long-
term tolerability of lenalidomide and are consistent with its estab-
lished safety profile. Without the strict inclusion and exclusion
criteria of randomized clinical studies, this EU PASS provides data
on the real-world use and safety of lenalidomide plus dexametha-
sone, offering a more complete perspective of the safety profile. The
results of this EU PASS are consistent with the recently published
results of a smaller (n ¼ 98 at 16 sites), German, noninterventional,
observational study of lenalidomide plus dexamethasone in patients
with RRMM.30
Although cross-trial comparisons must be interpreted with
caution, it is valuable to compare the real-world results from the
lenalidomide cohort of the EU PASS with those from theClinical Lymphoma, Myeloma & Leukemia October 2020 - e637
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e638lenalidomide groups of the MM-009 and MM-010 clinical trials.
Grade 3/4 neutropenia was lower in the EU PASS than in both
MM-009 and MM-010 (20.1% vs. 41.2% and 29.5%, respec-
tively), whereas grade 3/4 thrombocytopenia was similar (10.0% vs.
14.7% and 11.4%, respectively). Grade 3/4 infections were re-
ported in 14.3% of patients in the EU PASS, which is lower than
the frequency reported for “any infection” in MM-009 (21.5%) but
higher than the frequencies of “upper respiratory infection” (1.7%)
and “all other infection” (11.4%) in MM-010. Grade 3/4 VTE was
reported markedly less frequently in the EU PASS than in MM-009
and MM-010 (2.9% vs. 14.7% and 11.4%, respectively). This is
likely attributable to differences in thromboembolic prophylaxis use.
Per standard treatment practices at the times of the studies,
thromboprophylaxis was not required in MM-009 and not rec-
ommended in MM-010. Recommendations have since changed,31
and 71.0% of patients in the lenalidomide cohort of the EU
PASS were receiving thromboembolic prophylaxis at baseline.
Overall, the frequencies of AEs of special interest reported in the
lenalidomide cohort of the EU PASS were mostly lower than or
similar to those reported in the lenalidomide groups of the MM-009
and MM-010 clinical trials.
As per the nature of observational research, there was no
randomization of treatments, and the decision to treat a patient was
made prior to the decision to include a patient in this study.
Therefore, different factors may have affected treatment allocation
and contributed to bias. For instance, the severity of a patient’s
disease may have influenced the investigator’s treatment choice.
Additionally, a higher proportion of patients in the lenalidomide
cohort (54.7%) than in the background cohort (28.3%) had
received  2 therapies prior to study enrollment, which likely
correlates to a greater morbidity and susceptibility to AEs among
those patients, because disease severity typically increases with
subsequent lines of therapy.Conclusion
In conclusion, no new safety signals for lenalidomide were
identified in the EU PASS, which is the largest prospective real-
world European study of lenalidomide in RRMM undertaken to
date. The results of this study demonstrate that the safety profile of
lenalidomide plus dexamethasone in patients with RRMM in a real-
world setting is comparable to that seen in clinical trials of lenali-
domide in the RRMM setting. These findings have confirmed the
established safety profile of lenalidomide for patients with RRMM
in a real-world setting.
Clinical Practice Points
 Lenalidomide is an approved agent and a standard treatment
option for patients with RRMM based on the results of multiple
clinical trials
 There is a need to explore outcomes in patients with RRMM
who may not qualify for clinical trial participation but are
routinely encountered in clinical practice, especially because
many will receive long-term treatment
 The real-world findings observed in patients with RRMM in this
prospective European post-authorization safety study confirm the- Clinical Lymphoma, Myeloma & Leukemia October 2020established toxicity profile of lenalidomide; no new safety signals
were observed
 These results will provide clinicians with better insight regarding
the use of lenalidomide in their patients, many of whom will
have different patient and disease characteristics than those
included in clinical trialsAcknowledgments
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Supplemental Table 2 Neuropathy Status of Patients in the Lenalidomide Cohort During the First 12 Months of Study Participation
Time of
Assessmenta
Lenalidomide Cohort (n [ 2150)
Patients With
Neuropathy, nb
Motor Neuropathyc Sensory Neuropathyc
Grade 1 or 2, n (%)d,e Grade 3 or 4, n (%)d,e Grade 1 or 2, n (%)d,e Grade 3 or 4, n (%)d,e
Baseline 806 267 (33.1) 35 (4.3) 653 (81.0) 46 (5.7)
Month 1 671 209 (31.1) 22 (3.3) 515 (76.8) 29 (4.3)
Month 2 589 179 (30.4) 16 (2.7) 456 (77.4) 21 (3.6)
Month 3 487 142 (29.2) 9 (1.8) 377 (77.4) 17 (3.5)
Month 4 427 120 (28.1) 8 (1.9) 328 (76.8) 12 (2.8)
Month 5 349 103 (29.5) 6 (1.7) 269 (77.1) 13 (3.7)
Month 6 293 88 (30.0) 7 (2.4) 226 (77.1) 12 (4.1)
Month 7 252 72 (28.6) 9 (3.6) 190 (75.4) 11 (4.4)
Month 8 215 56 (26.0) 7 (3.3) 162 (75.3) 7 (3.3)
Month 9 195 52 (26.7) 5 (2.6) 149 (76.4) 6 (3.1)
Month 10 171 44 (25.7) 4 (2.3) 123 (71.9) 7 (4.1)
Month 11 155 46 (29.7) 4 (2.6) 115 (74.2) 6 (3.9)
Month 12 131 40 (30.5) 4 (3.1) 100 (76.3) 6 (4.6)
aRelative to time of enrollment for each patient.
bPatients with both motor and sensory neuropathy were counted once.
cFor each row, the combined amount of patients reported in the Motor Neuropathy and Sensory Neuropathy columns may not equal the value reported in the Patients With Neuropathy column because
some patients reported both motor and sensory neuropathy, and some patients had neuropathy of unknown grading.
dPercentages based off value in the Patients with Neuropathy column in the same row.
eNational Cancer InstituteeCommon Terminology Criteria version 3.0 was used for grading the status of neuropathy.










(n [ 137) Other (n [ 155) Total (n [ 1479)
Discontinuations 2150 (100) 1187 (100) 137 (100) 155 (100) 1479 (100)
Owing to disease
progressionb
695 (32.3) 189 (15.9) 35 (25.5) 40 (25.8) 264 (17.8)
Owing to adverse events 487 (22.7) 238 (20.1) 29 (21.2) 16 (10.3) 283 (19.1)
Otherc 504 (23.4) 162 (13.6) 24 (17.5) 28 (18.1) 214 (14.5)
Death 167 (7.8) 43 (3.6) 5 (3.6) 11 (7.1) 59 (4.0)
Owing to lack of therapeutic
effectd
90 (4.2) 69 (5.8) 9 (6.6) 14 (9.0) 92 (6.2)
Patient in remission 88 (4.1) 42 (3.5) 6 (4.4) 4 (2.6) 52 (3.5)
Completed course of
treatment as plannede
45 (2.1) 424 (35.7) 27 (19.7) 35 (22.6) 486 (32.9)
Patient lost to follow-up 38 (1.8) 12 (1.0) 2 (1.5) 3 (1.9) 17 (1.1)
Withdrawal of consent 36 (1.7) 6 (0.5) 0 1 (0.6) 7 (0.5)
Missing 0 2 (0.2) 0 3 (1.9) 5 (0.3)
aData reflect the primary reason for treatment discontinuation as selected by the investigator. Adverse events may have contributed to treatment discontinuation without being selected as the primary
reason for discontinuation.
bOnly the patients in the lenalidomide cohort were to be observed until progressive disease or death.
c
“Other” reasons (free text responses) included such categories as physician decisions, moving to transplant, or empty field on case record form.
dOther than disease progression.
e
“Completed course of treatment as planned” is applicable for background cohort patients, who had a defined treatment duration; for lenalidomide cohort patients, this applied to those patients who
received the drug as induction therapy before stem cell transplant or those from terminated sites where queries could not be issued.
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Supplemental Table 3 Overview of TEAEs
Patients With ‡ 1








(n [ 137) Other (n [ 155) Total (n [ 1479)
TEAE 1999 (93.0) 973 (82.0) 122 (89.1) 112 (72.3) 1207 (81.6)
Related TEAE 1615 (75.1) 745 (62.8) 92 (67.2) 66 (42.6) 903 (61.1)
Grade 3/4 TEAE 1245 (57.9) 486 (40.9) 60 (43.8) 61 (39.4) 607 (41.0)
Related grade 3/4 TEAE 829 (38.6) 292 (24.6) 22 (16.1) 29 (18.7) 343 (23.2)
TEAE leading to death
(grade 5 TEAE)c
300 (14.0) 64 (5.4) 10 (7.3) 14 (9.0) 88 (5.9)
Serious TEAE 973 (45.3) 335 (28.2) 46 (33.6) 49 (31.6) 430 (29.1)
Related serious AE 393 (18.3) 114 (9.6) 15 (10.9) 16 (10.3) 145 (9.8)
TEAE leading to
discontinuation
739 (34.4) 298 (25.1) 47 (34.3) 25 (16.1) 370 (25.0)
Related TEAE leading to
discontinuation
409 (19.0) 203 (17.1) 29 (21.2) 15 (9.7) 247 (16.7)
TEAE leading to dose
reduction
516 (24.0) 254 (21.4) 24 (17.5) 23 (14.8) 301 (20.4)
TEAE leading to dose
interruption
993 (46.2) 370 (31.2) 40 (29.2) 39 (25.2) 449 (30.4)
TEAE leading to dose
interruption and reduction
229 (10.7) 69 (5.8) 5 (3.6) 3 (1.9) 77 (5.2)
Abbreviations: AE ¼ adverse event; TEAE ¼ treatment-emergent adverse event.
aTreatment cohorts are defined according to the starting treatment, but patients could have taken other drugs in combination with the main assigned drug.
bA patient with multiple occurrences of an AE is counted only once in the AE category.
cIncludes any death occurring for any reason, including progressive disease, on or after the first treatment of the study medication and within 30 days after the last dose.
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Supplemental Table 4 Most Common (‡ 10% of Patients) Any Grade TEAEs in the Lenalidomide Cohort or Background Cohort
System Organ Class
Preferred Term, n (%)a,b
Lenalidomide Cohort Background Cohort
Lenalidomide (n [ 2150) Bortezomib (n [ 1187) Thalidomide (n [ 137) Other (n [ 155)
All TEAEs Related TEAEs All TEAEs Related TEAEs All TEAEs Related TEAEs All TEAEs Related TEAEs
Hematologic 968 (45.0) 829 (38.6) 274 (23.1) 214 (18.0) 31 (22.6) 20 (14.6) 51 (32.9) 36 (23.2)
Neutropenia 534 (24.8) 488 (22.7) 69 (5.8) 63 (5.3) 14 (10.2) 11 (8.0) 22 (14.2) 19 (12.3)
Anemia 471 (21.9) 335 (15.6) 114 (9.6) 67 (5.6) 17 (12.4) 7 (5.1) 26 (16.8) 10 (6.5)
Thrombocytopenia 425 (19.8) 365 (17.0) 154 (13.0) 134 (11.3) 10 (7.3) 5 (3.6) 22 (14.2) 18 (11.6)
General disorders and
administration-site conditions
938 (43.6) 509 (23.7) 346 (29.1) 193 (16.3) 49 (35.8) 31 (22.6) 41 (26.5) 16 (10.3)
Fatigue 287 (13.3) 214 (10.0) 108 (9.1) 85 (7.2) 27 (19.7) 24 (17.5) 12 (7.7) 6 (3.9)
Pyrexia 291 (13.5) 72 (3.3) 90 (7.6) 24 (2.0) 11 (8.0) 3 (2.2) 14 (9.0) 6 (3.9)
Asthenia 266 (12.4) 139 (6.5) 94 (7.9) 46 (3.9) 10 (7.3) 3 (2.2) 14 (9.0) 5 (3.2)
Gastrointestinal disorders 770 (35.8) 438 (20.4) 353 (29.7) 222 (18.7) 44 (32.1) 30 (21.9) 27 (17.4) 11 (7.1)
Diarrhea 338 (15.7) 194 (9.0) 138 (11.6) 85 (7.2) 8 (5.8) 3 (2.2) 9 (5.8) 3 (1.9)
Constipation 213 (9.9) 124 (5.8) 137 (11.5) 82 (6.9) 28 (20.4) 23 (16.8) 7 (4.5) 3 (1.9)
Nervous system disorders 620 (28.8) 395 (18.4) 478 (40.3) 418 (35.2) 55 (40.1) 45 (32.8) 19 (12.3) 9 (5.8)
Peripheral neuropathy 98 (4.6) 79 (3.7) 200 (16.8) 192 (16.2) 11 (8.0) 10 (7.3) 1 (0.6) 1 (0.6)
Abbreviations: AE ¼ adverse event; MedDRA ¼ Medical Dictionary for Regulatory Activities; TEAE ¼ treatment-emergent adverse event.
aA patient with multiple occurrences of an AE is counted only once in the AE category.




















Supplemental Table 5 AEs of Special Interest Occurring Within 4 Months of Start of Study Treatment
MedDRA SMQ or
HLT, n (%)
Lenalidomide Cohort Background Cohort
Lenalidomide (n [ 2150) Bortezomib (n [ 1187) Thalidomide (n [ 137) Other (n [ 155) Total (n [ 1479)
All TEAEs Grade 3/4 TEAEs All TEAEs Grade 3/4 TEAEs All TEAEs Grade 3/4 TEAEs All TEAEs Grade 3/4 TEAEs All TEAEs Grade 3/4 TEAEs
Infections 624 (29.0) 175 (8.1) 320 (27.0) 100 (8.4) 29 (21.2) 10 (7.3) 36 (23.2) 10 (6.5) 385 (26.0) 120 (8.1)
Neutropenia 397 (18.5) 271 (12.6) 78 (6.5) 47 (4.0) 15 (10.9) 8 (5.8) 22 (14.2) 16 (10.3) 115 (7.8) 71 (4.8)
Thrombocytopenia 327 (15.2) 144 (6.7) 167 (14.1) 95 (8.0) 8 (5.8) 3 (2.2) 19 (12.3) 6 (3.9) 194 (13.1) 104 (7.0)
Neuropathy 121 (5.6) 14 (0.7) 300 (35.3) 51 (4.3) 16 (11.7) 3 (2.2) 2 (1.3) 0 318 (21.5) 54 (3.7)
Renal failure 111 (5.2) 49 (2.3) 39 (3.3) 25 (2.1) 4 (2.9) 3 (2.2) 5 (3.2) 5 (3.2) 48 (3.2) 33 (2.2)
Rash 92 (4.3) 7 (0.3) 20 (1.7) 0 5 (3.6) 0 1 (0.6) 0 26 (1.8) 0
Bleeding events 72 (3.3) 11 (0.5) 42 (3.5) 9 (0.8) 4 (2.9) 2 (1.5) 2 (1.3) 1 (0.6) 48 (3.2) 12 (0.8)
Venous
thromboembolism
63 (2.9) 26 (1.2) 11 (0.9) 5 (0.4) 0 0 3 (1.9) 0 14 (0.9) 5 (0.3)
Cardiac failure 38 (1.8) 13 (0.6) 12 (1.0) 6 (0.5) 1 (0.7) 1 (0.7) 2 (1.3) 2 (1.3) 15 (1.0) 9 (0.6)
Cardiac arrhythmias 33 (1.5) 12 (0.6) 18 (1.5) 9 (0.8) 0 0 3 (1.9) 2 (1.3) 21 (1.4) 11 (0.7)
Hypersensitivity 2 (0.1) 0 3 (0.3) 0 0 0 0 0 3 (0.2) 0
Hyperthyroidism 1 (<0.1) 0 1 (0.1) 0 0 0 0 0 1 (0.1) 0
QT prolongation 0 0 0 0 0 0 0 0 0 0













Supplemental Table 6 AEs of Special Interest Occurring Within 6 Months and After 6 Months of Initiation of Study Treatment in the
Lenalidomide Cohort
SMQ or HLT, n (%)
Lenalidomide (n [ 2150)
£6 Months >6 Monthsa
All TEAEs Grade 3/4 TEAEs All TEAEs Grade 3/4 TEAEs
Infections 724 (33.7) 212 (9.9) 424 (19.7) 113 (5.3)
Neutropenia 478 (22.2) 321 (14.9) 286 (13.3) 179 (8.3)
Thrombocytopenia 381 (17.7) 172 (8.0) 154 (7.2) 61 (2.8)
Neuropathy 150 (7.0) 20 (0.9) 76 (3.5) 10 (0.5)
Renal failure 131 (6.1) 60 (2.8) 52 (2.4) 29 (1.3)
Rash 97 (4.5) 8 (0.4) 30 (1.4) 0
Bleeding events 94 (4.4) 19 (0.9) 57 (2.7) 6 (0.3)
Venous thromboembolism 90 (4.2) 43 (2.0) 46 (2.1) 20 (0.9)
Cardiac failure 45 (2.1) 17 (0.8) 23 (1.1) 11 (0.5)
Cardiac arrhythmias 38 (1.8) 14 (0.7) 28 (1.3) 9 (0.4)
Hypersensitivity 2 (0.1) 0 3 (0.1) 0
Hypothyroidism 2 (0.1) 0 4 (0.2) 1 (<0.1)
Abbreviations: AE ¼ adverse event; HLT ¼ high-level term; MedDRA ¼ Medical Dictionary for Regulatory Activities; SMQ ¼ Standardized MedDRA Query; TEAE ¼ treatment-emergent adverse event.
aIncludes any AE that started or worsened > 6 months after treatment began. AEs that started within the first 6 months of treatment but worsened > 6 months after treatment began are only counted
as occurring > 6 months after treatment began. Percentages are based on the total safety population in the lenalidomide cohort (n ¼ 2150). For the lenalidomide cohort, 1143 patients were still
receiving treatment after 6 months.
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